Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Sanofi, Glenmark In Pain Meds Deal

by Ann M. Thayer
May 10, 2010 | A version of this story appeared in Volume 88, Issue 19

In its first pharmaceutical research partnership in India, Sanofi-Aventis has licensed drug candidates for treating chronic pain from India’s Glenmark Pharmaceuticals. In return, Glenmark will receive an up-front fee and milestone payments that could total $325 million, as well as potential royalties. The agents are vanilloid receptor antagonists, which inhibit the TRPV3 receptor, an ion-channel protein that mediates and influences cell signaling. One candidate is in Phase I clinical development for treating diabetic neuropathic and osteoarthritic pain.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.